OBJECTIVES: Explore the epidemiology and treatment of soft tissue sarcoma (STS) in EU5. METHODS: Epidemiology of STS was derived from the Kantar Health (KH) CancerMPact database, sources for which include country specific cancer registries, published scientific studies and proprietary physician surveys conducted in March 2015 comprising 76 doctors seeing an average of 3,210 STS patients per month.  Country specific age and gender incidence rates were applied to country population data to determine number of newly diagnosed STS patients.  Annual non-metastatic and metastatic progression rates and annual non-metastatic and metastatic survival rates are used to calculate total number of surviving patients up to 10 years after diagnosis.  Treatment data was determined from the physician surveys and was country specific. RESULTS: Incidence of STS ranged from 3.1 – 4.1 per 100K . Among all incident STS patients, 74% were non metastatic and 16% were metastatic.  Surgery/Drug/Radiation rates were, respectively, 43%/37%/19% in France, 52%/42%/22% in Germany, 49%/31%/27% in Italy, 41%/34%/29% in Spain and 45%/28%/27% in the UK.  Among metastatic patients, 41% to 44% received a first line drug.  There was wide variation in the % of first line that received second line (range 35% - 58%) and second line who received third (17% - 30%).  Among first line drug treated doxorubicin plus ifosfamide was the preferred regimen in France, Germany and Spain whereas doxorubicin monotherapy was preferred in UK.  Trabectedin and pazopanib were used relatively frequently as second or third line treatments. CONCLUSIONS: This study confirms the rarity of soft tissue sarcoma in EU5. Doxorubicin plus ifosfamide is the most commonly used treatment in first line across EU5, trabectedin and pazopanib tend to be the most utilized treatments in second and third line. Variance to the trend is apparent in France and Spain second line and in France and UK third line.